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Two new PCR assays (for Ralstonia species and Ralstonia respiraculi), together with previously published PCR
assays, were used to assess Ralstonia isolates recovered from 111 cystic fibrosis patients. Ralstonia mannitoli-
lytica accounted for 46% of isolates, while R. respiraculi and Ralstonia pickettii accounted for 19% and 18%,
respectively. Ralstonia basilensis and Ralstonia metallidurans, species not previously recovered from human
samples, were also identified.
Persons with cystic fibrosis (CF) are particularly susceptible
to pulmonary infections with a wide range of bacteria (11).
Typical pathogens include Staphylococcus aureus, Haemophilus
influenzae, Pseudomonas aeruginosa, and members of the Burk-
holderia cepacia complex (11, 16). During the last decade,
many other gram-negative, nonfermenting bacterial species,
including Stenotrophomonas maltophilia, Achromobacter xy-
losoxidans, and Pandoraea sp., have also been recovered from
CF patients’ sputum (1, 2, 4, 9). While the frequency of infec-
tion with these species is relatively low and their clinical sig-
nificance unclear, they present a significant challenge to diag-
nostic laboratories, as they are difficult to identify and often
misidentified as B. cepacia complex.
Among the unusual organisms recovered from CF patients
are several Ralstonia species. Currently, the genus Ralstonia
consists of 14 validly described species. Among these, Ralstonia
pickettii, Ralstonia mannitolilytica, Ralstonia gilardii, Ralstonia
paucula, Ralstonia taiwanensis, Ralstonia insidiosa, and Ralsto-
nia respiraculi have been recovered from various clinical
sources, including respiratory secretions of CF patients. How-
ever, because of the rapidly changing taxonomy of this genus
and the lack of rapid and reliable methods for species identi-
fication, the occurrence and clinical role of Ralstonia sp. have
not been systematically investigated. We have recently de-
scribed sensitive and specific PCR assays for the identification
of several of these species, including R. mannitolilytica, R. pick-
ettii, and R. insidiosa (3, 6). In the present study, we developed
two additional PCR assays, one for the identification of all
Ralstonia spp. (i.e., at the genus level) and another targeting R.
respiraculi. We used these new assays, together with the previ-
ously published assays, to assess the distribution of Ralstonia
species recovered from CF patients in the United States.
To design primers for the new PCR assays, we aligned rel-
evant 16S rRNA gene sequences available in the GenBank
database by using the MegAlign software package (DNAStar
Inc., Madison, WI). These included 242 sequences from 14
validly described Ralstonia species, putative novel Ralstonia
species, and several other phylogenetically related -Pro-
teobacteria and CF-relevant species. Primer pair RalGS-F and
RalGS-R was designed to amplify a fragment of the 16S rRNA
genes of all Ralstonia species, while primer pair Rres-F and
Rres-R targeted species-specific signature sequences in vari-
able regions V3 and V8a of the 16S rRNA gene of R. respi-
raculi (Table 1).
DNA for use in PCR assays was prepared from bacteria as
described previously (15). DNA amplification was carried out
in reaction mixtures containing 2.0 mM MgCl2, 50 mM KCl, 20
mM Tris-HCl (pH 8.4), 250 M (each) deoxynucleoside
triphosphate (Promega, Madison, WI), 0.4 M of each primer,
1 U of Taq polymerase (Invitrogen, Carlsbad, California), 2 l
of DNA and adjusted to 25 l by the addition of high-perfor-
mance liquid chromatography-grade H2O. For the Ralstonia
genus-level PCR, amplification was carried out in a RapidCy-
cler (Idaho Technologies Inc., Salt Lake City, Utah) thermo-
controller. After denaturation at 95°C for 30 s, 30 amplification
cycles were completed, each consisting of 20 s at 94°C, 20 s at
58°C, and 40 s at 72°C. A final extension of 1 min at 72°C was
applied. For the R. respiraculi-specific PCR, amplification was
carried out in a PTC-100 (MJ Research, Reno, NV) thermo-
cycler. After an initial 2-min denaturation at 95°C, 26 ampli-
fication cycles were completed, each consisting of 30 s at 94°C,
30 s at 62°C, and 1 min at 72°C, followed by an additional final
extension of 5 min at 72°C. Negative-control PCRs with all
reaction components except template DNA were included in
every experiment. PCR assays employing each primer pair
produced DNA products of the predicted sizes (Fig. 1).
In order to confirm PCR-based identification results, we
performed comparative 16S rRNA gene sequence analysis.
Nearly complete 16S rRNA genes (corresponding to positions
9 to 1500 in the Escherichia coli numbering system) were am-
plified by PCR using Pfu DNA polymerase (Stratagene, La
Jolla, CA) with conserved primers UFPL and URPL as previ-
ously described (15). DNA sequencing was carried out with an
Applied Biosystems ABI model 3700 sequencer and the pro-
tocols of the manufacturer (PE Applied Biosystems, Foster
City, CA) by using the BigDye Terminator cycle sequencing
ready reaction kit. Resultant sequences were visualized as
chromatograms and manually edited using Chromas v.2.22
(Technelysium Pty. Ltd., Helensvale, Australia). Edited se-
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quences were assembled using EditSeq (DNAStar Inc.) and
identified by using BLASTN and comparison to sequences
currently available in the NCBI database (www.ncbi.nlm.nih
.gov/BLAST).
R. respiraculi strains were further assessed by whole-cell pro-
tein analysis. Strains were grown on tryptone soy agar for 48 h
at 37°C, and preparation of whole-cell proteins and sodium
dodecyl sulfate-polyacrylamide gel electrophoresis were per-
formed as described previously (18). Densitometric analysis,
normalization and interpolation of the protein profiles, and
numerical analysis using the Pearson product moment corre-
lation coefficient were performed using the GelCompar 4.2
software package (Applied Maths, Sint-Martens-Latem, Bel-
gium). Isolates were identified by comparison to a database
containing profiles of all Burkholderia, Ralstonia, Alcaligenes,
Achromobacter, Pandoraea, and Bordetella species (2).
To assess the sensitivity and specificity of the new Ralstonia
genus-specific PCR assay, we tested a set of 152 strains that
included 92 strains representing 13 Ralstonia species and 60
strains representing 23 other CF-relevant species. More spe-
cifically, this set of 152 strains included 12 Ralstonia strains
obtained from the BCCM/LMG bacteria collection (Labora-
torium voor Microbiologie, Universiteit Gent, Ghent, Bel-
gium): Ralstonia eutropha LMG 1199T, Ralstonia basilensis
LMG 18990T, Ralstonia solanacearum LMG 2299T, R. gilardii
LMG 5886T, R. paucula LMG 3245T, Ralstonia oxalatica LMG
2235T, R. taiwanensis LMG 19424T, R. taiwanensis LMG 19464,
Ralstonia campinensis LMG 19282T, R. campinensis LMG
19285, Ralstonia metallidurans LMG 1195T, and R. metalli-
durans LMG 18526. The remaining 80 Ralstonia strains were
recovered from 80 CF patients and referred for analysis to the
Burkholderia cepacia Research Laboratory and Repository
(University of Michigan). These were identified as Ralstonia by
either previously published PCR assays (3, 6) (33 R. mannito-
lilytica isolates, 17 R. pickettii isolates, and 2 R. insidiosa iso-
lates) or 16S rRNA gene sequence analysis (13 R. respiraculi
isolates, 8 R. gilardii isolates, 2 R. metallidurans isolate, 1 R.
taiwanensis isolate, 1 R. paucula isolate, 1 R. basilensis isolate,
and 2 strains classified as Ralstonia). The identification of the
13 R. respiraculi isolates in this set was further confirmed by
whole-cell protein analysis (described above). Another 60 bac-
terial strains had been identified in previous studies (4, 5, 14,
15, 17, 20, 21) as belonging to 23 non-Ralstonia species. This
group included 24 B. cepacia complex strains, 11 Pandoraea
species strains, 7 A. xylosoxidans strains, 5 Burkholderia gladioli
strains, 5 P. aeruginosa strains, 2 S. maltophilia strains, 2 Her-
baspirillum species strains, and 1 strain each of Bordetella bron-
chiseptica, H. influenzae, S. aureus, and Serratia marcescens.
Both the sensitivity and specificity of the novel Ralstonia genus-
specific PCR assay were 100% (Table 2).
The sensitivity and specificity of the putative R. respiraculi-
specific PCR were determined by testing 53 strains. This group
included 13 strains identified as R. respiraculi by polyphasic
testing that included 16S rRNA gene sequence analysis and
whole-cell protein analysis. The 40 remaining strains repre-
sented 12 other Ralstonia species as well as A. xylosoxidans and
all species within the B. cepacia complex and the genus Pan-
doraea. The sensitivity and specificity of this assay were 100%
(Table 2).
To assess the distribution of Ralstonia species in persons
with CF, isolates from an additional 31 Ralstonia-infected CF
patients, which had been referred to the Burkholderia cepacia
Research Laboratory and Repository during the course of the
PCR validation studies, were combined with the 80 Ralstonia
CF isolates described above to provide a total of 111 isolates
from 111 CF patients. These patients received care in 56 CF
care centers in 24 U.S. cities. All isolates had been identified as
Ralstonia species by using previously published PCR assays
FIG. 1. PCR analysis of Ralstonia respiraculi, Ralstonia species, and CF-relevant bacteria. (A) PCR using Ralstonia genus-specific primers
RalGS-F and RalGS-R. (B) PCR using R. respiraculi-specific primers Rres-F and Rres-R. Lanes M, reference markers; lanes 1, R. mannitolilytica;
lanes 2, R. pickettii; lanes 3 to 6, R. respiraculi; lanes 7, R. gilardii; lanes 8, R. insidiosa; lanes 9, R. paucula; lanes 10, R. metallidurans; lanes 11, R.
taiwanenesis; lanes 12, R. eutropha; and lanes 13, negative control (water).
TABLE 1. 16S rRNA gene-based primer sets
Primer target Annealingtemp (°C) Primer Sequence (5–3) Location
a Product
size (bp)
All Ralstonia species 58 RalGS-F CTGGGGTCGATGACGGTA 452–469 546
RalGS-R ATCTCTGCTTCGTTAGTGGC 979–998
R. respiraculi 62 Rres-F GTCCGGAAAGAAATGGCG 423–440 1,011
Rres-R TCCTTGCGGTTAGGCTACCC 1415–1434
a Positions are relative to the 16S rRNA gene sequence of Ralstonia solanacearum (NC 003295).
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(specific for R. pickettii, R. mannitolilytica, or R. insidiosa), the
novel R. respiraculi and Ralstonia genus-level PCR assays de-
scribed above, or whole-cell protein and 16S rRNA gene se-
quence analysis (for species for which no PCR assay is avail-
able). The distribution of Ralstonia species among these
patients is shown in Table 3. Two isolates were clearly identi-
fied as Ralstonia species based on whole-cell protein and 16S
rRNA gene sequence analysis but could not be placed defini-
tively into an existing species within this genus.
This distribution confirms the trend observed in a previous,
smaller-scale study (6) in which R. mannitolilytica was found to
be the predominant Ralstonia species recovered from respira-
tory secretions of CF patients, followed by R. pickettii and R.
respiraculi. The present study also reiterates the fact that other
Ralstonia species, including R. gilardii, R. insidiosa, and R.
paucula, can be recovered from respiratory secretions of CF
patients. Surprisingly, we also identified two R. metallidurans
strains and a single R. basilensis strain. Both of these species
are environmental organisms known for their metal resistance
and ability to degrade a wide range of recalcitrant xenobiotics
(12, 19). To our knowledge, neither species has been previously
reported to be involved in human or veterinary infections.
Whether these species were causing active infection in these
patients or merely transiently colonizing their respiratory tracts
remains unclear in the absence of clinical data. Nevertheless,
the recovery of these species again highlights the facts that
unusual microorganisms may be recovered from the respira-
tory secretions of CF patients (2) and that additional studies of
the disease-causing potential of such species are needed.
Although considerable efforts have been made over the past
several years to gain a better understanding of the biodiversity
of Ralstonia species recovered from various ecological niches,
including the respiratory tracts of CF patients (3, 7), strains
that remain refractory to identification despite the use of state-
of-the-art methods continue to be found. In the present study,
we identified two strains that, based on comparative sequence
analysis of the 16S rRNA gene sequence, clearly belong to the
genus Ralstonia. Analysis of their protein profiles clearly sug-
gested that they belong to two novel Ralstonia species. More
in-depth polyphasic analyses will be required to determine the
taxonomic status of these strains.
Identification of Ralstonia species is difficult, and misidenti-
fication as Pseudomonas fluorescens or B. cepacia complex is
frequent (8, 10, 13). Therefore, identification of Ralstonia spe-
cies based on conventional methods should be confirmed with
molecular (PCR-based) assays. We have previously described
PCR assays for the identification of R. mannitolilytica, R. pick-
ettii, and R. insidiosa (3, 6), and as is the case with the assays
developed in the present study, these showed excellent sensi-
tivity and specificity. Thus, reliable (i.e., sensitive and specific)
PCR-based assays are now available for the genus-level iden-
tification of Ralstonia species as a whole, as well as for the
species-level identification of R. insidiosa and the Ralstonia
species most frequently recovered from patients with CF (i.e.,
R. mannitolilytica, R. pickettii, and R. respiraculi). Accurate
identification of these species is a necessary prerequisite to
further studies aimed at determining the clinical relevance of
these species to CF.
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gene sequences generated in this study were deposited in Gen-
Bank under accession numbers AY860224 through AY860251.
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